Corvus Pharmaceuticals Stock Analysis

Corvus Stock Analysis Notes

About 59.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.99. Corvus Pharmaceuticals had not issued any dividends in recent years. Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company was incorporated in 2014 and is based in Burlingame, California. Corvus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more info on Corvus Pharmaceuticals please contact the company at 650 900 4520 or go to https://www.corvuspharma.com.

Corvus Pharmaceuticals Investment Alerts

Corvus Pharmaceuticals Upcoming and Recent Events

Corvus Largest EPS Surprises

View All Earnings Estimates

Corvus Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Corvus Pharmaceuticals Thematic Classifications

Corvus Stock Institutional Investors

Note, although Corvus Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Corvus Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 273.09 M.

Corvus Profitablity

Management Efficiency

Corvus Pharmaceuticals has return on total asset (ROA) of (0.283) % which means that it has lost $0.283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0048) %, meaning that it created substantial loss on money invested by shareholders. Corvus Pharmaceuticals' management efficiency ratios could be used to measure how well Corvus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.95 in 2025. Return On Capital Employed is likely to drop to -0.86 in 2025. At this time, Corvus Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 72.5 M in 2025, whereas Other Assets are likely to drop 0.86 in 2025.

Technical Drivers

As of the 26th of March, Corvus Pharmaceuticals shows the Mean Deviation of 3.98, risk adjusted performance of (0.06), and Standard Deviation of 6.12. Corvus Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Corvus Pharmaceuticals information ratio and kurtosis to decide if Corvus Pharmaceuticals is priced correctly, providing market reflects its regular price of 4.25 per share. Given that Corvus Pharmaceuticals has information ratio of (0.09), we suggest you to validate Corvus Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Corvus Pharmaceuticals Price Movement Analysis

Corvus Pharmaceuticals Insider Trading Activities

Corvus Pharmaceuticals Outstanding Bonds

Corvus Pharmaceuticals Predictive Daily Indicators

Corvus Pharmaceuticals Corporate Filings

Corvus Pharmaceuticals Forecast Models

Corvus Pharmaceuticals' time-series forecasting models are one of many Corvus Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Corvus Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Corvus Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Corvus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Corvus Pharmaceuticals. By using and applying Corvus Stock analysis, traders can create a robust methodology for identifying Corvus entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Corvus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Corvus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Corvus Pharmaceuticals stock analysis indicators help investors evaluate how Corvus Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Corvus Pharmaceuticals shares will generate the highest return on investment. By understating and applying Corvus Pharmaceuticals stock analysis, traders can identify Corvus Pharmaceuticals position entry and exit signals to maximize returns.

When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.